Cyclin-dependent kinase inhibitors: efficacy and safety

Кононенко, И. Б.; Снеговой, А. В.; Сельчук, В. Ю.

doi:10.21518/2079-701x-2019-10-42-55

Cited by 3 publications

(2 citation statements)

References 54 publications

(86 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Также рибоциклиб применяется в комбинации с фулвестрантом у женщин в постменопаузе с гормонозависимым и HER2-отрицательным РМЖ четвертой стадии в качестве терапии первой линии или на фоне прогрессирования заболевания с использованием другого лечения. Эффективность и безопасность рибоциклиба в комбинации с летрозолом, фулвестрантом и тамоксифеном + гозерелин изучены в ходе III фазы трех клинических исследований MONALEESA (2, 3, 7) [25]. Низкомолекулярный ингибитор тирозинкиназ HER2 и EGFR лапатиниб применяется в комбинации с летрозолом для лечения HER2-положительного мРМЖ у женщин в постменопаузе.…”

Section: особенности гормонотерапии метастатического рака молочной же...unclassified

Updated Breast Cancer Hormonal Therapy Paradigm

Костецкая¹,

Лемешевский²,

Батян³

2022

Евразийский Онкологический Журнал

View full text Add to dashboard Cite

Рак молочной железы является наиболее общей причиной онкологической заболеваемости женщин в мире и второй общей причиной смертности женщин от рака. Однако, несмотря на достигнутый прогресс в лечении раннего рака молочной железы, значительные проблемы остаются в отношении стратегии ведения прогрессирующего рака молочной железы. Приблизительно у 20–40% пациенток, подвергшихся радикальному лечению, развивается метастатическая форма опухолевой болезни. За последние 20 лет разработаны новые модели лечения рака молочной железы с улучшенной клинической эффективностью, что продемонстрировано в крупных рандомизированных клинических исследованиях. Установлено преимущество новых соединений в качестве первой линии лечения метастатического рака молочной железы. Основная цель данной статьи – представить главные этапы совершенствования стратегии гормонального лечения и сфокусироваться на центральной роли эндокринотерапии в лечении рака молочной железы. Breast cancer worldwide is the most common malignancy afflicting women and is the second most common cause of death from cancer. Despite the progress made in early disease, considerable challenges remain with respect to the management of advanced breast cancer. Approximately 20–40% of patients with breast cancer treated initially with curative intent will ultimately develop metastatic disease. The last 20 years have resulted in the development of a new mode of treatment of breast cancer with improved clinical efficacy having been demonstrated in the largest randomized clinical study. The possible advantages of new compounds as a first-line treatment have established in the metastatic and adjuvant setting. The aim of this article is to highlight the main stages in their development and to focus on the central role which endocrine therapy has played in the treatment of breast cancer.

show abstract

Section: особенности гормонотерапии метастатического рака молочной же...unclassified

Updated Breast Cancer Hormonal Therapy Paradigm

Костецкая¹,

Лемешевский²,

Батян³

2022

Евразийский Онкологический Журнал

View full text Add to dashboard Cite

show abstract

“…Интерес представляют данные о роли серинтреонин киназы Aurora-A (Aur-A) в механизмах чувствительности к тамоксифену. Показано, что истощение данного белка, который вовлечен в процессы регуляции митоза и клеточного цикла, повышает чувствительность эстроген-позитивных клеточных линий РМЖ к тамоксифену [51]. В работе продемонстрировано, что селективный ингибитор Aur-A MLN8237, который в настоящее время проходит клинические испытания, синергично взаимодействует с тамоксифеном и ингибирует рост тамоксифен-резистентных клеточных линий.…”

Section: пути преодоления резистентности к тамоксифену на основе исслunclassified

Role of Cyclin D1 in the Mechanisms of Tamoxifen Resistance

et al. 2020

View full text Add to dashboard Cite

Hormone-receptor positive breast cancer is the most common molecular subtype and represents 60–75 % of all breast cancers (BC). The presence of specific molecular targets such as the estrogen/progesterone receptor determines the use of hormone therapy for patients with this subtype. Tamoxifen, a selective estrogen receptor modulator, remains the first adjuvant treatment choice for the hormone-receptor positive BC patients. However, tamoxifen resistance is the major limitation of its efficacy. In this regard, the study of drug resistance mechanisms as well as search for biological prognostic markers of tamoxifen efficacy is very important. Cyclin D1 is a representative of the regulatory protein family, which plays a central role in the cell cycle regulation. The data on the association between cyclin D1 and estrogen-dependent signaling as well as the characteristics of CCND1 gene and its most studied polymorphic loci, were presented. The prognostic significance of cyclin D1 in hormone-receptor positive BC receptor-positive breast cancer was described. The experimental and clinical studies data on the association between the cyclin D1 expression level and tamoxifen efficacy are analyzed. Current approaches to overcoming hormone resistance based on cyclin D1 studies were considered.

show abstract

Clinical aspects of the use of ribociclib

Маркович¹,

Kalugin²,

Гордеева³

et al. 2020

Medicinskij sovet

View full text Add to dashboard Cite

Luminal metastatic HER2-negative breast cancer remains one of the most common cancers in oncological practice. This disease still remains incurable. Endocrine therapy remained the standard therapy of choice for disseminated patients for a long time. The search for new effective drugs, development of strategies that can overcome primary and secondary resistance to endocrinotherapy has shown that the CDK4/6-inhibitors group can improve not only the short-term treatment outcomes, but also affect the overall survival of patients, which has been demonstrated in a number of phase III studies. Along with that, the use of CDK4/6 inhibitors maintains a good quality of life, allows patients to maintain professional and social activities, which is of great importance for long-term prospects. Given that the endocrine therapy combined with CDK4/6-inhibitors today is the new standard of therapy in patients with luminal HER2- negative breast cancer, knowing how to use this therapy in daily clinical practice is crucial. Know and apply innovative drugs in clinical practice and the management of regimen toxicity always my work demands close application. This article provides an overview of the data on the efficacy of ribociclib based on phase III registration studies. It also presents its own clinical experience demonstrating the feasibility of using a new group of drugs in patients both in pre- and postmenopausal women. The authors discussed the issues related to the modification of the regimen due to the toxicity of therapy, in particular, neutropenia and hepatotoxicity. They also showed the possibility of managing adverse events with the preservation of a long-term effect with no loss in quality of life.

show abstract

Cyclin-dependent kinase inhibitors: efficacy and safety

Cited by 3 publications

References 54 publications

Updated Breast Cancer Hormonal Therapy Paradigm

Updated Breast Cancer Hormonal Therapy Paradigm

Role of Cyclin D1 in the Mechanisms of Tamoxifen Resistance

Clinical aspects of the use of ribociclib

Contact Info

Product

Resources

About